Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia

Research Study Number PLAT-03
 
Principal Investigator Colleen Annesley, MD
 
Phase Pilot

Research Study Description

This study will enroll patients who have been enrolled into study PLAT-02 and meet the entry criteria for study PLAT-03.

Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number PLAT-03
 
Contact Colleen Annesley, MD
 
Telephone 206/987-2106
 
E-mail
 

Keywords: Leukemia, Acute Lymphoblastic (ALL); Hematologic Malignancies; Leukemia; Pediatric Cancers, Miscellaneous; Neoplasms; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials